What is Altimmune's market cap?

Altimmune (ALT) has a market capitalization of $581.5M and trades on NASDAQ.

Who are Altimmune's competitors?

Altimmune's key competitors include Madrigal Pharmaceuticals, Viking Therapeutics, Eli Lilly, and others. These companies compete in similar markets and product categories.

Who does Altimmune partner with?

Altimmune's notable partners include AIM-MASH AI Assist.

What subsidiaries does Altimmune have?

Altimmune's subsidiaries include Spitfire Pharma Inc..

Where is Altimmune headquartered?

Altimmune is headquartered in United States of America and employs approximately 59 people. It has been publicly traded since 2005.

Altimmune

ALT

Altimmune, Inc. is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapies for serious liver diseases and metabolic disorders.

Market cap

$581.48M+62.9%

Net income-$91.1M-0.9%

Free cash flow-$68.8M+10.2%

EPS (diluted)-$0.92+27.0%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 13, 2026

EPS-$0.18Beat by $0.07

Read the full report

Next report

Aug 11, 2026 (In 3 weeks)

Revenue estimate$1.8K

EPS estimate-$0.15

Financials

Q1 2026

Income statement

See full

Operating income-$24.2M-11.1%

Net income-$22.6M-15.3%

EPS (diluted)-$0.18+30.8%

Balance sheet

See full

Cash & equivalents$97.6M+98.7%

Total debt$34.8M+14,092%

Total equity$284.0M+99.8%

Total assets$335.6M+113%

Cash flow

See full

Operating cash flow-$20.9M-24.4%

CapEx$21.0K—

Free cash flow-$21.0M—

Valuation & ratios

Valuation

See full

Market cap$581.48M+62.9%

Enterprise value$518.6M+156%

Returns & leverage

See full

Return on equity-42.7%-8.7pp

Debt / equity0.1×+0.1×

Current ratio29.6×+13.7×

Competitors

By market cap

Eli Lilly$1.05T+51.0%

Merck & Co.$306.33B+49.9%

Madrigal Pharmaceuticals, Inc.$12.2B+91.8%

Viking Therapeutics$4.4B+30.5%

Wave Life Sciences$1.1B+5.9%

Altimmune$581.5M+56.5%

Galectin Therapeutics$302.9M+129%

MTV

MetaVia$10.3M-17.8%

By revenue growth

Madrigal Pharmaceuticals, Inc.+257%

Eli Lilly+47.4%

Merck & Co.+2.9%

Wave Life Sciences-32.9%

By net margin

Eli Lilly34.99%+12.3pp

Merck & Co.13.59%-13.7pp

Madrigal Pharmaceuticals, Inc.-27.32%+96.1pp

Wave Life Sciences-66.5%-88.8pp

Altimmune-214,860.98%—

Profile

Altimmune, Inc. is a late clinical-stage biopharmaceutical company focused on developing novel peptide-based therapies for serious liver diseases and metabolic disorders. The company's core value proposition centers on its balanced dual-receptor agonist technology designed to address liver fat, inflammation, and fibrosis while promoting weight loss and lean muscle preservation.

Competitive position

Altimmune is a late-stage clinical developer with a differentiated 1:1 balanced glucagon/GLP-1 agonist that has received FDA Breakthrough Therapy and Fast Track designations.

GeographiesUnited States, Europe

Customer segmentsPatients, Healthcare Providers

Business modelResearch and Development, Biotechnology R&D

SuppliersPeptide manufacturing, Clinical research organizations (CROs), Specialized AI pathology tool providers

CustomersSpecialty pharmacies, Hospitals, Metabolic disease specialists, Hepatologists

CountryUnited States of America

Listed2005

Employees59.0

CEOJerome Benedict Durso

SectorHealthcare

IndustryBiotechnology

Websitealtimmune.com

FilingsSEC EDGAR

Questions, answered.

What is Altimmune's market cap?: Altimmune (ALT) has a market capitalization of $581.5M and trades on NASDAQ.
Who are Altimmune's competitors?: Altimmune's key competitors include Madrigal Pharmaceuticals, Viking Therapeutics, Eli Lilly, and others. These companies compete in similar markets and product categories.
Who does Altimmune partner with?: Altimmune's notable partners include AIM-MASH AI Assist.
What subsidiaries does Altimmune have?: Altimmune's subsidiaries include Spitfire Pharma Inc..
Where is Altimmune headquartered?: Altimmune is headquartered in United States of America and employs approximately 59 people. It has been publicly traded since 2005.